<p>Annexon（纳斯达克股票代码：ANNX - 获取免费报告）于周四公布了季度财报。该公司报告季度每股收益为（$0.23），超出市场共识预期的（$0.30）$0.07，FiscalAI 报道。</p>
<h2>Annexon 股票表现</h2>
<p>周四，纳斯达克 ANNX 的交易价格下跌了 $0.18，达到 $5.52。该公司的股票交易量为 2,357,564 股，而其平均交易量为 2,106,709 股。该公司的市值为 $897.06 百万，市盈率为 -4.06，贝塔系数为 1.22。Annexon 的 12 个月最低价为 $1.60，最高价为 $7.18。该公司的 50 日移动平均价格为 $5.69，200 日移动平均价格为 $5.08。</p>
<h2>分析师设定新目标价</h2>
<p>几位股票研究分析师最近对 ANNX 股票发表了评论。Cantor Fitzgerald 在 1 月 14 日的研究报告中重申了对 Annexon 股票的 “增持” 评级。Chardan Capital 在 3 月 20 日的研究报告中重申了 “买入” 评级，并设定了 $16.00 的目标价。最后，Weiss Ratings 在 4 月 20 日的研究报告中重申了对 Annexon 股票的 “卖出（d-）” 评级。五位投资分析师对该股票给予了买入评级，一位给予了持有评级，一位给予了卖出评级。根据 MarketBeat.com 的数据，Annexon 目前的平均评级为 “适度买入”，共识目标价为 $17.00。</p>
<p><strong>获取我们关于 Annexon 的最新股票报告</strong></p>
<h2>内部人士买卖</h2>
<p>在其他 Annexon 的新闻中，执行副总裁 Ted Yednock 于 2 月 18 日出售了 7,857 股 Annexon 股票。股票以平均价格 $5.11 出售，总价值为 $40,149.27。交易后，该执行副总裁直接持有 97,227 股公司股票，价值约 $496,829.97。此次交易使其持股比例减少了 7.48%。该交易已在向 SEC 提交的文件中披露，可以通过此超链接访问。此外，执行副总裁 Dean Richard Artis 于 2 月 18 日出售了 5,290 股 Annexon 股票。股票以平均价格 $5.10 出售，总交易额为 $26,979.00。交易完成后，该执行副总裁持有 123,487 股公司股票，价值约 $629,783.70。这代表其持股比例减少了 4.11%。有关此次出售的更多细节可在官方 SEC 披露中找到。内部人士在上个季度共出售了价值 $165,973 的 32,513 股公司股票。公司内部人士持有公司股票的 11.87%。</p>
<h2>机构资金流入和流出</h2>
<p>机构投资者最近买卖了该公司的股票。Landscape Capital Management L.L.C. 在第四季度以 $50,000 的估值收购了 Annexon 的新股份。CIBC Bancorp USA Inc. 在第三季度以约 $31,000 的价格收购了 Annexon 的新股份。Mercer Global Advisors Inc. ADV 在第四季度以约 $52,000 的价格收购了 Annexon 的新股份。Engineers Gate Manager LP 在第二季度以约 $32,000 的价格收购了 Annexon 的新股份。最后，Cerity Partners LLC 在第四季度以约 $74,000 的价格收购了 Annexon 的新股份。</p>
<h2>关于 Annexon</h2>
<p>（获取免费报告）</p>
<p>Annexon Inc 是一家临床阶段的生物技术公司，专注于为神经退行性和神经免疫疾病患者发现和开发靶向补体的疗法。该公司的研究平台集中在抑制 C1 复合体，这是经典补体途径的关键启动因子，涉及多种罕见且危及生命的疾病。通过选择性地靶向上游补体激活，Annexon 旨在防止异常的免疫介导损伤，这种损伤是吉兰 - 巴雷综合症（GBS）和自身免疫性神经病等疾病的特征。</p>
<p>Annexon 的管线核心是 ANX005，这是一种针对 C1q 亚单位的人源化单克隆抗体，目前正在进行急性 GBS 和慢性神经退行性疾病的二期临床试验。</p>
<h2>了解更多</h2>
<ul>
<li>我们更看好的五只股票比 Annexon 更好</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QU5OWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="650" height="325" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QU5OWA"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 $1,000 在 Annexon 吗？</h2>
<p>在你考虑 Annexon 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前立即购买……而 Annexon 并不在名单上。</p>
<p>虽然 Annexon 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

ANNX

纳斯达克生物科技指数 ETF - iShares Nasdaq

2 倍做多纳斯达克生物技术 ETF - ProShares

标普生物技术 3 倍做多 - Direxion

纽交所高增长板生物技术指数 ETF - First Trust

标普生物技术 ETF - SPDR

IBBQ

生物科技 ETF - VanEck Vectors

医药突破 ETF - ALPS

动态生物技术与基因组 ETF - Invesco

<p>Annexon（纳斯达克代码：ANNX）报告的季度收益为每股亏损 0.23 美元，超出预期 0.07 美元。该股交易下跌至 5.52 美元，市值为 8.9706 亿美元。分析师的评级各不相同，五位推荐买入，一位推荐卖出。近期内部人士出售了 32,513 股。机构投资者也表现出兴趣，获得了新头寸。Annexon 专注于针对神经退行性疾病的补体靶向疗法，其主要产品 ANX005 正在进行第二阶段临床试验</p>

<p>Annexon (NASDAQ:ANNX - Get Free Report) announced its quarterly earnings results on Thursday. The company reported ($0.23) EPS for the quarter, topping the consensus estimate of ($0.30) by $0.07, FiscalAI reports.</p>
<div class="lb-trans"><p>Annexon（纳斯达克股票代码：ANNX - 获取免费报告）于周四公布了季度财报。该公司报告季度每股收益为（$0.23），超出市场共识预期的（$0.30）$0.07，FiscalAI 报道。</p>
</div><h2>Annexon Stock Performance</h2>
<div class="lb-trans"><h2>Annexon 股票表现</h2>
</div><p>NASDAQ ANNX traded down $0.18 during trading on Thursday, reaching $5.52. The company's stock had a trading volume of 2,357,564 shares, compared to its average volume of 2,106,709. The firm has a market cap of $897.06 million, a price-to-earnings ratio of -4.06 and a beta of 1.22. Annexon has a twelve month low of $1.60 and a twelve month high of $7.18. The business's fifty day moving average price is $5.69 and its 200-day moving average price is $5.08.</p>
<div class="lb-trans"><p>周四，纳斯达克 ANNX 的交易价格下跌了 $0.18，达到 $5.52。该公司的股票交易量为 2,357,564 股，而其平均交易量为 2,106,709 股。该公司的市值为 $897.06 百万，市盈率为 -4.06，贝塔系数为 1.22。Annexon 的 12 个月最低价为 $1.60，最高价为 $7.18。该公司的 50 日移动平均价格为 $5.69，200 日移动平均价格为 $5.08。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析师设定新目标价</h2>
</div><p>Several equities research analysts recently commented on ANNX shares. Cantor Fitzgerald reiterated an &#34;overweight&#34; rating on shares of Annexon in a research note on Wednesday, January 14th. Chardan Capital reiterated a &#34;buy&#34; rating and set a $16.00 price target on shares of Annexon in a research note on Friday, March 20th. Finally, Weiss Ratings reiterated a &#34;sell (d-)&#34; rating on shares of Annexon in a research note on Monday, April 20th. Five investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, Annexon presently has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $17.00.</p>
<div class="lb-trans"><p>几位股票研究分析师最近对 ANNX 股票发表了评论。Cantor Fitzgerald 在 1 月 14 日的研究报告中重申了对 Annexon 股票的 “增持” 评级。Chardan Capital 在 3 月 20 日的研究报告中重申了 “买入” 评级，并设定了 $16.00 的目标价。最后，Weiss Ratings 在 4 月 20 日的研究报告中重申了对 Annexon 股票的 “卖出（d-）” 评级。五位投资分析师对该股票给予了买入评级，一位给予了持有评级，一位给予了卖出评级。根据 MarketBeat.com 的数据，Annexon 目前的平均评级为 “适度买入”，共识目标价为 $17.00。</p>
</div><p><strong>Get Our Latest Stock Report on Annexon</strong></p>
<div class="lb-trans"><p><strong>获取我们关于 Annexon 的最新股票报告</strong></p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>内部人士买卖</h2>
</div><p>In other Annexon news, EVP Ted Yednock sold 7,857 shares of Annexon stock in a transaction on Wednesday, February 18th. The shares were sold at an average price of $5.11, for a total value of $40,149.27. Following the transaction, the executive vice president directly owned 97,227 shares in the company, valued at approximately $496,829.97. The trade was a 7.48% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Dean Richard Artis sold 5,290 shares of Annexon stock in a transaction on Wednesday, February 18th. The shares were sold at an average price of $5.10, for a total transaction of $26,979.00. Following the completion of the transaction, the executive vice president owned 123,487 shares in the company, valued at approximately $629,783.70. This represents a 4.11% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 32,513 shares of company stock valued at $165,973 in the last quarter. Corporate insiders own 11.87% of the company's stock.</p>
<div class="lb-trans"><p>在其他 Annexon 的新闻中，执行副总裁 Ted Yednock 于 2 月 18 日出售了 7,857 股 Annexon 股票。股票以平均价格 $5.11 出售，总价值为 $40,149.27。交易后，该执行副总裁直接持有 97,227 股公司股票，价值约 $496,829.97。此次交易使其持股比例减少了 7.48%。该交易已在向 SEC 提交的文件中披露，可以通过此超链接访问。此外，执行副总裁 Dean Richard Artis 于 2 月 18 日出售了 5,290 股 Annexon 股票。股票以平均价格 $5.10 出售，总交易额为 $26,979.00。交易完成后，该执行副总裁持有 123,487 股公司股票，价值约 $629,783.70。这代表其持股比例减少了 4.11%。有关此次出售的更多细节可在官方 SEC 披露中找到。内部人士在上个季度共出售了价值 $165,973 的 32,513 股公司股票。公司内部人士持有公司股票的 11.87%。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><p>Institutional investors have recently bought and sold shares of the business. Landscape Capital Management L.L.C. acquired a new position in Annexon in the fourth quarter valued at $50,000. CIBC Bancorp USA Inc. acquired a new position in shares of Annexon during the third quarter worth about $31,000. Mercer Global Advisors Inc. ADV acquired a new position in shares of Annexon during the fourth quarter worth about $52,000. Engineers Gate Manager LP acquired a new position in shares of Annexon during the second quarter worth about $32,000. Finally, Cerity Partners LLC acquired a new position in shares of Annexon during the fourth quarter worth about $74,000.</p>
<div class="lb-trans"><p>机构投资者最近买卖了该公司的股票。Landscape Capital Management L.L.C. 在第四季度以 $50,000 的估值收购了 Annexon 的新股份。CIBC Bancorp USA Inc. 在第三季度以约 $31,000 的价格收购了 Annexon 的新股份。Mercer Global Advisors Inc. ADV 在第四季度以约 $52,000 的价格收购了 Annexon 的新股份。Engineers Gate Manager LP 在第二季度以约 $32,000 的价格收购了 Annexon 的新股份。最后，Cerity Partners LLC 在第四季度以约 $74,000 的价格收购了 Annexon 的新股份。</p>
</div><h2>About Annexon</h2>
<div class="lb-trans"><h2>关于 Annexon</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Annexon Inc is a clinical-stage biotechnology company focused on the discovery and development of complement-targeted therapies for patients with neurodegenerative and neuroimmune diseases. The company's research platform centers on the inhibition of the C1 complex, a key initiator of the classical complement pathway implicated in several rare and life-threatening disorders. By selectively targeting upstream complement activation, Annexon aims to prevent the aberrant immune-mediated damage that characterizes conditions such as Guillain-Barré syndrome (GBS) and autoimmune neuropathies.</p>
<div class="lb-trans"><p>Annexon Inc 是一家临床阶段的生物技术公司，专注于为神经退行性和神经免疫疾病患者发现和开发靶向补体的疗法。该公司的研究平台集中在抑制 C1 复合体，这是经典补体途径的关键启动因子，涉及多种罕见且危及生命的疾病。通过选择性地靶向上游补体激活，Annexon 旨在防止异常的免疫介导损伤，这种损伤是吉兰 - 巴雷综合症（GBS）和自身免疫性神经病等疾病的特征。</p>
</div><p>At the core of Annexon's pipeline is ANX005, a humanized monoclonal antibody directed against the C1q subcomponent, currently in Phase 2 clinical trials for acute GBS and chronic neurodegenerative indications.</p>
<div class="lb-trans"><p>Annexon 的管线核心是 ANX005，这是一种针对 C1q 亚单位的人源化单克隆抗体，目前正在进行急性 GBS 和慢性神经退行性疾病的二期临床试验。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>了解更多</h2>
</div><ul>
<li>Five stocks we like better than Annexon</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比 Annexon 更好</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QU5OWA" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&amp;Symbol=ANNX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Annexon Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 $1,000 在 Annexon 吗？</h2>
</div><p>Before you consider Annexon, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Annexon 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Annexon wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前立即购买……而 Annexon 并不在名单上。</p>
</div><p>While Annexon currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Annexon 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

Annexon (NASDAQ:ANNX) Announces Quarterly Earnings Results, Beats Expectations By $0.07 EPS

Market Beat

Annexon

Invesco Nasdaq Biotechnology ETF

Annexon（NASDAQ:ANNX）公布季度财报，每股收益超出预期 0.07 美元